

Rajiv Dhand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4129547/publications.pdf>

Version: 2024-02-01

23
papers

1,930
citations

686830

13
h-index

676716

22
g-index

24
all docs

24
docs citations

24
times ranked

2038
citing authors

#	ARTICLE	IF	CITATIONS
1	Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines. Chest, 2005, 127, 335-371.	0.4	659
2	Aerosol drug delivery: developments in device design and clinical use. Lancet, The, 2011, 377, 1032-1045.	6.3	416
3	Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 651-659.	2.5	285
4	The Role of Nebulized Therapy in the Management of COPD: Evidence and Recommendations. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 58-72.	0.7	87
5	Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 300-304.	0.7	85
6	The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 1-11.	0.7	81
7	Asthma in Adult Patients with COVID-19. Prevalence and Risk of Severe Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 893-905.	2.5	74
8	Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective. Pulmonary Therapy, 2021, 7, 345-376.	1.1	37
9	Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports. Advances in Therapy, 2020, 37, 1812-1828.	1.3	35
10	Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. Respiratory Care, 2018, 63, 833-839.	0.8	24
11	Inhaled Drug Therapy 2016: The Year in Review. Respiratory Care, 2017, 62, 978-996.	0.8	23
12	<p>Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler<p>, International Journal of COPD, 2019, Volume 14, 509-523.	0.9	23
13	Airborne Particulate Concentrations During and After Pulmonary Function Testing. Chest, 2021, 159, 1570-1574.	0.4	17
14	Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia. , 2020, 2, e0307.		17
15	Aerosol therapy for asthma. Current Opinion in Pulmonary Medicine, 2000, 6, 59-70.	1.2	15
16	The Impact of Inhaler Device Regimen in Patients with Asthma or COPD. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3033-3040.e1.	2.0	14
17	Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease. Cleveland Clinic Journal of Medicine, 2018, 85, S19-S27.	0.6	11
18	Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease. International Journal of COPD, 2022, Volume 17, 79-92.	0.9	8

#	ARTICLE	IF	CITATIONS
19	Aerosol delivery systems for treating obstructive airway diseases during the SARS-CoV-2 pandemic. Internal and Emergency Medicine, 2021, 16, 2035-2039.	1.0	7
20	Maintenance Therapy with Nebulizers in Patients with Stable COPD: Need for Reevaluation. Pulmonary Therapy, 2020, 6, 177-192.	1.1	7
21	Mitigating Viral Dispersion during Respiratory Support Procedures in the ICU. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1051-1053.	2.5	2
22	COPD in Primary Care: Key Considerations for Optimized Management: Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease. Journal of Family Practice, 2018, 67, S19-S27.	0.2	2
23	Pulmonary Therapy 2020 Update and Podcast: Meet the Journal's Editors-in-Chief. Pulmonary Therapy, 2020, 6, 1-7.	1.1	1